Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies
Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.
In this episode of The Vitals, Beth Finley-Oliver, MSN, ARNP, AGNP-BC, a nurse practitioner who works in the outpatient hematology clinic at Moffitt Cancer Center, revisits her presentation from the 2023 JADPRO Live Annual Meeting and discusses the growing number of therapies for patients with relapsed or refractory multiple myeloma.
Episode Highlights
“A clinical trial upfront would be my first option. After that, I have to try and find something their myeloma hasn't seen yet.”
“With CAR T, the CRS incidence is higher, and I think we're doing better [at managing it] because we have multiple interventions. We see viral infections with [both] the CAR T and the bispecifics. We always have to kind of keep that in the back of our mind.”
“The more medications we have, the more this is turning into a chronic illness.”
For More On Multiple Myeloma:
- Delivering Teclistamab in the Outpatient Setting
- Ambulation Improves Frailty Scores in Patients With Multiple Myeloma
- With New Bispecific Antibodies in Multiple Myeloma, Nurses Need To Know How to Manage CRS
Video Interviews
- Managing Teclistamab-Induced CRS for Patients With Multiple Myeloma
- Data Supporting Elranatamab Approval in Multiple Myeloma
- Data Behind Talquetamab Approval in Multiple Myeloma
More Podcast Episodes
Belantamab Mafodotin Combo Yields Improved OS in Relapsed/Refractory Multiple Myeloma
December 12th 2024Updated data from the DREAMM-7 trial support the use of belantamab mafodotin plus bortezomib/dexamethasone as a potential new standard of care in relapsed or refractory multiple myeloma, according to Vania Hungria, MD, PhD.
Adding Daratumumab to VRd Improves MRD Response in Newly Diagnose Myeloma
December 8th 2024An expanded analysis from the phase 3 CEPHEUS trial showed that daratumumab plus VRd improved MRD responses as well as progression-free survival among patients with transplant-ineligible or -deferred newly diagnosed multiple myeloma.
